Member Info for BaxtersSoup

Sharedealer, l am sure she’s doing just fine!

Hi Fig, yes.... all business should resume shortly And positively here and the other.
GL mate.

Things looking good for Q4.

Ppip, for a company valued at just £16.5mn with 64mn shares in issue just shows how volatile this tiny bio is. We witnessed just a sharp spike upwards that became too extreme so profit taking caused this to fall to the 20’s.

No we are consolidating for the next leg up and even a conservative mkt cap would be £30mn so 40’s is probably fair value now.

Very excited at the next barrage of news-flow in the coming weeks!

Only a hunch but l would not be surprised if the claims provision is in excess of what is required and so this could be eventually added to the free cash float.

I also think as soon as we have a date of when lending can be resumed, then l think we’ll be over 30p in quick succession...... a bit like a CINE RNS reversal!

Under 10p now
FCA Update next month
Lending to commence BEFORE year end
JB shennanigans gone
Dead wood left and their shares
CEO endorses with 500,000 buy
8@D

I’m thinking 20p first level, 35p next spring up and testing 1 year highs of 70p after lending resumed which l still have pencilled on my mind as starting next month?

Good luck Bankfool.
I believe the 20’s-30’s is now our news baseline in light of the next news.
Lots to come too!

Yeah, why sell now? doesn’t make sense. Plus its peanuts in the bigger dcheme of things - 1.78%. Lol.

What is more important is reading between the lines and why do it now.

I take this RNS as a positive to shake all the loose holders / small dilution before lending resumes and a re-rate Back in to the 20’s.

This a.m.

No its going back to Fridays close, lol.

Sorry Thoth, FYI $100 mn = £1.25 per VAL share and many Oncology deals are Complwted with a 30% success.

Val managed 54.5%!

Here you go Thoth -Phase l and I/ll up to a few dozen max.

Then Phase ll on +25 (next for VAL):

https://www.google.co.uk/amp/s/amp.cancer.org/treatment/treatments-and-side-effects/clinical-trials/what-you-need-to-know/phases-of-clinical-trials.html

Your next point Thoth ll:

“A dissection of five years' biopharma buyout spending reveals that most deals are struck over preclinical and mid-stage assets“

“ By comparison, 14 of the 30 phase II company buyouts involved prices above $100m. ”

https://www.google.co.uk/amp/s/www.evaluate.com/node/14296/amp

Read and weep!

The thing that resonates with 201 from Suzy’s interview on BRR is her saying that many oncology products have been advanced / commercialised at just 30%...... l think VAL will have little difficulty to do a deal with 54.5% with next to no side effects plus safe and tolerable. Happy days!
8@D

Yep, more than enough well covered and nearly there re:Vreq and commencing lending soon.
Rerate on the cards bwforehand IMHO

Well said Viera.

Think the base line 10p now is our springboard and can see a steady climb back to 20p in terms of a stabilisation in proceedings. JB may even make a bid (!), who knows, but things back on track IMHO with good progress with the FCA and a cash balance at £145mn that should be rising circa £5mn pm since last update, plus lending hopefully resuming next month.

10p is a bargain so just patience needed and this saga will all blow over and looking for 20p as first move up then 35p and next 75p 12 month high. Calm required.

Well done everyone.

Back to VAL and the wonderful Suzy!

Already reported him and his avatars to LSE and also on the ADFN channel and locating his IP and where he is connected to l guess.